Mark Andrew Rothera's Insider Trades & SAST Disclosures
Mark Andrew Rothera's most recent trade in Viracta Therapeutics Inc was a trade of 475,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Andrew Rothera.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viracta Therapeutics Inc | Mark Andrew Rothera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 475,000 | 475,000 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Rothera Mark Andrew | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.49 per share. | 30 Nov 2023 | 52,094 | 52,094 | - | 0.5 | 25,734 | Common Stock |
| Viracta Therapeutics Inc | Rothera Andrew Mark | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.49 per share. | 30 Nov 2023 | 47,906 | 100,000 | - | 0.5 | 23,627 | Common Stock |
| Viracta Therapeutics Inc | Mark Andrew Rothera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Mark Andrew Rothera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 1,375,000 | 1,375,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges